Market volatility spurs M&A talks at UK biotechs

Up until last week, Renovo was the poster child for success in the UK's biotech industry. Then after one of its therapies failed a drug trial for one indication, investors bailed and cut its stock price in half. And the analysts say the cutthroat response has raised fears about the sudden swings in stock price that can afflict any emerging drug developer.

"We need a success," Cannacord's Karl Keegan told the Financial Times. "I was hoping that Renovo would be a straightforward success story that would attract the more general small-cap investor but those have now been turned away."

The volatility in the market has opened the doors to M&A talks at a growing number of biotech companies. The FT notes that Ardana has announced plans to sell or merge and CeNeS Pharmaceuticals has confirmed that it is in takeover talks.

- read the story in the Financial Times

Related Articles:
Renovo shares plunge even after 'buy' signals. Report
Mixed data for Renovo's scarring therapy. Report
Renovo inks $875M deal for scarring drug. Report
Dealmaking stays big even as the markets tremble. Report

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.